We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Citigroup
C
$222B
| $283M | 0.66% |
4,728,498
-51,429
| -1% | -$3.04M |
|
27
Coca-Cola
KO
$354B
| $279M | 0.65% |
6,568,375
-21,293
| -0.3% | -$888K |
|
28
Visa
V
$677B
| $274M | 0.64% |
3,082,933
+46,939
| +2% | +$4.04M |
|
29
UnitedHealth
UNH
$382B
| $271M | 0.63% |
1,650,832
+24,255
| +1% | +$3.97M |
|
30
Philip Morris
PM
$301B
| $270M | 0.63% |
2,391,611
+19,386
| +0.8% | +$2M |
|
31
IBM
IBM
$202B
| $264M | 0.62% |
1,584,578
+17,601
| +1% | +$2.95M |
|
32
Oracle
ORCL
$331B
| $239M | 0.56% |
5,356,466
+122,747
| +2% | +$5.11M |
|
33
Amgen
AMGN
$203B
| $216M | 0.5% |
1,314,521
+18,213
| +1% | +$3.03M |
|
34
3M
MMM
$89B
| $211M | 0.49% |
1,320,085
+13,459
| +1% | +$2.06M |
|
35
Altria Group
MO
$122B
| $204M | 0.48% |
2,853,312
+39,264
| +1% | +$2.84M |
|
36
Walmart Inc
WMT
$871B
| $194M | 0.45% |
8,081,388
+243,174
| +3% | +$5.6M |
|
37
Medtronic
MDT
$107B
| $190M | 0.44% |
2,357,173
+122,793
| +5% | +$9.59M |
|
38
McDonald's
MCD
$188B
| $188M | 0.44% |
1,449,024
-4,619
| -0.3% | -$580K |
|
39
SLB Ltd
SLB
$77.8B
| $185M | 0.43% |
2,366,849
+21,026
| +0.9% | +$1.72M |
|
40
Mastercard
MA
$477B
| $182M | 0.43% |
1,618,300
+11,277
| +0.7% | +$1.24M |
|
41
Boeing
BA
$165B
| $161M | 0.38% |
910,108
-33,385
| -4% | -$5.69M |
|
42
AbbVie
ABBV
$458B
| $160M | 0.37% |
2,455,314
+7,181
| +0.3% | +$451K |
|
|
CELG
43
DELISTED
Celgene Corp
CELG
| $159M | 0.37% |
1,280,003
+10,679
| +0.8% | +$1.28M |
|
44
Union Pacific
UNP
$183B
| $155M | 0.36% |
1,464,974
+25,653
| +2% | +$2.74M |
|
45
Gilead Sciences
GILD
$161B
| $153M | 0.36% |
2,258,902
+46,707
| +2% | +$3.28M |
|
46
Qualcomm
QCOM
$176B
| $152M | 0.35% |
2,646,712
+71,144
| +3% | +$4.13M |
|
47
Goldman Sachs
GS
$313B
| $151M | 0.35% |
658,734
+22,378
| +4% | +$5.4M |
|
48
US Bancorp
USB
$99.6B
| $150M | 0.35% |
2,914,382
+74,644
| +3% | +$3.98M |
|
49
Honeywell
HON
$77.1B
| $148M | 0.35% |
1,315,939
+24,850
| +2% | +$2.74M |
|
50
RTX Corp
RTX
$287B
| $148M | 0.34% |
2,089,794
+56,867
| +3% | +$3.99M |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.